Yaneth Trujillo, MD
Family Medicine · Weston, FLNPI 1184753246
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.
Across 115 payments — averaging $27.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$739
- Lilly USA, LLC$332
- Boehringer Ingelheim$245
- Pfizer$243
- Amgen$208
- Novo Nordisk$207
- plus $1K from 20 others
Across 66 payments — averaging $61,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.9M
- Genentech, Inc.$1M
- Bausch Health US, LLC$61K
- Lumos Diagnostics, Inc.$40K
- F. Hoffmann-la Roche AG$35K
- Amgen$29K
- plus $6K from 1 others
What the payments were for
- Food & beverage$3,15399%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $739 |
| Lilly USA, LLC | 21 | $332 |
| Boehringer Ingelheim | 6 | $245 |
| Pfizer | 12 | $243 |
| Amgen(2 entities) | 10 | $208 |
| Novo Nordisk | 11 | $207 |
| Amarin Pharma, Inc. | 7 | $201 |
| ANI Pharmaceuticals, Inc. | 2 | $160 |
| Abbott | 3 | $133 |
| Boston Scientific | 1 | $123 |
| Dexcom, Inc. | 5 | $119 |
| Exact Sciences | 4 | $115 |
| Redhill Biopharma Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Merck | 1 | $35 |
| AbbVie(2 entities) | 2 | $34 |
| GSK | 2 | $31 |
| Gilead | 2 | $31 |
| Tactile Systems Technology Inc | 1 | $25 |
| Eisai Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Vivus LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$234
- ANDEXXA$145
- PURIFIED CORTROPHIN GEL$125
- GENERAL PAIN MANAGEMENT$123
- JARDIANCE$109
- Vascepa$103
- FARXIGA$102
- BREZTRI$100
How this compares
$3,188 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $53,154 |
| JardianceEmpagliflozin | 15 | $22,982 |
| JanuviaSitagliptin Phosphate | 13 | $21,803 |
| MounjaroTirzepatide | 16 | $16,645 |
| AptiomEslicarbazepine Acetate | 11 | $16,180 |
| EliquisApixaban | 14 | $14,720 |
| Rosuvastatin Calcium | 95 | $2,345 |
| Atorvastatin Calcium | 190 | $2,179 |
| DilantinPhenytoin Sodium Extended | 15 | $1,800 |
| Losartan Potassium | 135 | $1,615 |
| Esomeprazole Magnesium | 25 | $1,550 |
| Omeprazole | 80 | $1,443 |
| Omega-3 Acid Ethyl Esters | 14 | $1,226 |
| Gabapentin | 56 | $1,164 |
| Levothyroxine Sodium | 142 | $1,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $207 | $53,15450 claims |
| Boehringer IngelheimJardiance | $245 | $22,98215 claims |
| MerckJanuvia | $35 | $21,80313 claims |
| Lilly USA, LLCMounjaro | $332 | $16,64516 claims |
| PfizerEliquis, Dilantin | $243 | $16,52029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Weston
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.